FRONT ONCOL 润色咨询

Frontiers in Oncology

出版年份：2011 年文章数：14479 投稿命中率： 开通期刊会员，数据随心看

出版周期：Irregular 自引率：2.1% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2023-05-05 ms2000000984739514 来自浙江省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向：肿瘤;罕见基因变异;案例报道
    经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！
    2022.12.14号，提交Manuscript，Initial Validation
    2022.12.19号，Editorial Assignment 稿件分配编辑
    2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立
    2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应
    2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内
    2023.03.16，Interactive review交互评审
    2023.03.24，提交第一轮审稿意见和修改稿
    2023.03.28，Review Finalized
    2023.04.07，accepted
    2023.04.12，Author's Proof，要求两天内提交
    2023.04.25，支付版面费，2020 USD，限期一个月
    2023.04.28，在线发表。

    4

    展开4条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2024-03-21 ms4000000517261689 来自山东省

    偏重的研究方向：肿瘤;免疫治疗;生信
    经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2024-01-31 mastermaus 来自湖北省

    审稿速度:1.0
    偏重的研究方向：诊断;肿瘤;临床
    经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2024-03-11 第一篇一定要中啊 来自江苏省

    审稿速度:24.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤
    经验分享：其实是很难的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2021-09-17 146e0980m70暂无昵称

    审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0
    偏重的研究方向：肿瘤
    经验分享：来还愿了
    修回3天后审稿人全部endorse
    第4天就直接accept了
    从投稿到接收差不多两个月左右，这个速度简直感激

    71

    展开71条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2023-08-03 ms3000001338105201 来自广东省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向：症状管理;急性白血病
    经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023
    Editorial assignment start date: 13 Jun 2023
    Independent review start date: 19 Jun 2023
    Interactive review activated date: 05 Jul 2023
    Review finalized date: 24 Jul 2023
    Final validation date: 02 Aug 2023
    Manucript accepted: 02 Aug 2023

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2023-02-13 ms8000000438373883 来自江西省

    收临床case report吗

    3

    展开3条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2024-02-05 决战 来自湖北省

    审稿速度:6.0 | 投稿命中率:25.0
    经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2024-02-05 决战 来自湖北省

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤
    经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：肿瘤;罕见基因变异;案例报道<br>经验分享：文章见刊了，好开心，之前参考了大家的投稿经验，分享一下我的投稿历程，传递好运！<br>2022.12.14号，提交Manuscript，Initial Validation <br>2022.12.19号，Editorial Assignment 稿件分配编辑<br>2023.01.23号，Independent Review Report, Reviewer 1返回审稿意见，这个审稿人提的意见很专业，态度中立<br>2023.03.14号，两个月没动静，给编辑发了一封催稿邮件，得到回应<br>2023.03.15号，Reviewer 2返回审稿意见，直接同意发表，审稿意见还是需要在编辑界面单独回复的，限期14天内<br>2023.03.16，Interactive review交互评审<br>2023.03.24，提交第一轮审稿意见和修改稿<br>2023.03.28，Review Finalized<br>2023.04.07，accepted <br>2023.04.12，Author's Proof，要求两天内提交<br>2023.04.25，支付版面费，2020 USD，限期一个月<br>2023.04.28，在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向：肿瘤;免疫治疗;生信<br>经验分享：这个需要多久到分配编辑呀，在initial validation 4.5天了…… 生信又做了6个验证试验，不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向：诊断;肿瘤;临床<br>经验分享：临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向：肿瘤<br>经验分享：来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右，这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：症状管理;急性白血病<br>经验分享：来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114449, encodeId=65d6211444918, content=收临床case report吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3a6513284, createdName=ms8000000438373883, createdTime=Mon Feb 13 16:53:23 CST 2023, time=2023-02-13, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2185997, encodeId=c0ab218599e4a, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：十一月中旬投的搞，80多天了，依然还在Independent Review，就回来一个审稿意见，服了，处理速度贼慢，都想撤稿选其他杂志投了，当时投觉得发文量大，所以就投这个，没想到这么坑。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 13:57:01 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2186002, encodeId=a83d2186002d0, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：投稿快三个月了，还在independent review，才回来一个审稿意见，意见感觉不太行，都想撤稿了，太慢了，非常耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=22ec5549526, createdName=决战, createdTime=Mon Feb 05 14:09:45 CST 2024, time=2024-02-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2142329, encodeId=c2152142329ca, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：胃肠肿瘤<br>经验分享：Received date: 14 Mar 2023<br>Editorial assignment start date: 02 Mar 2023<br>Independent review start date: 26 Mar 2023<br>Interactive review activated date: 17 Apr 2023<br>Review finalized date: 05 May 2023<br>Final validation date: 05 May 2023<br><br>到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭<br>有没有大神给支个招，这是要拒还是怎么回事呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18a6547377, createdName=每次投稿都要遇见心软的神, createdTime=Mon Jun 12 09:16:41 CST 2023, time=2023-06-12, status=1, ipAttribution=河南省)]
    2023-06-12 每次投稿都要遇见心软的神 来自河南省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：胃肠肿瘤
    经验分享：Received date: 14 Mar 2023
    Editorial assignment start date: 02 Mar 2023
    Independent review start date: 26 Mar 2023
    Interactive review activated date: 17 Apr 2023
    Review finalized date: 05 May 2023
    Final validation date: 05 May 2023

    到现在停在Final validation已经1个多月了，还是没动静，催了编辑一次，回信说还不确定需要多长时间，会尽快给出FINIAL DECISION。蚌埠住了，F系列现在也那么难投了吗？/哭
    有没有大神给支个招，这是要拒还是怎么回事呀？

    1

    展开1条回复
共500条页码: 2/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分